相关实验视频
Updated: Jul 5, 2025

06:08
A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
23.5K
我们对原发性阿尔多斯特罗尼主义的了解和新发现
Natalia Ekman1, Ashley B Grossman2, Dorota Dworakowska1
1Department of Hypertension & Diabetology, Medical University of Gdańsk, 80-214 Gdańsk, Poland.
International journal of molecular sciences
|January 23, 2024
概括
原发性阿尔多斯特隆症 (PA) 是一种常见的,可治愈的高血压的原因,经常被错过. 早期诊断和治疗,包括手术或药物治疗,可以改善心血管结果,并有效管理二次高血压.
科学领域:
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 原发性阿尔多斯特隆症 (PA) 影响5-10%的高血压患者,是可治愈的二次高血压的原因.
- 关键原因包括双边异常性缩 (BIH) 和阿尔多生成腺瘤 (APA).
- 高血压导致高血压,/水的保留,和的损失,心血管风险增加独立于血压.
研究的目的:
- 审查对原发性阿尔多斯特主义的诊断和管理的既定和新兴见解.
- 突出增强查和针对性治疗的准确亚型的重要性.
主要方法:
- 最初的查使用阿尔多斯特/雷宁比率 (ARR).
- 验证性测试以验证阳性ARR结果.
- 通过计算机断层扫描和上腺静脉采样进行亚型化,并可能使用放射性核素成像.
主要成果:
- 低血并不是一个可靠的指标,仅在28%的PA患者中存在.
- 肺炎患者心血管事件的发生率高于基本高血压患者.
- 治疗策略根据PA亚型而异:单边形式的手术,双边形式的矿物质皮质类抗体 (MRAs).
结论:
- 肺炎是一种普遍的,未被确诊的疾病,具有显著的心血管影响.
- 准确的诊断和分类方法对于有效的管理至关重要.
- 及时干预,根据PA的具体原因进行调整,可以显著改善患者的治疗结果.
相关概念视频
Adrenal Gland Disorders
1.5K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
1.5K
Hormonal Regulation
33.1K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.1K
Antihypertensive Drugs: Potassium-Sparing Diuretics
563
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
563
Antihypertensive Drugs: Direct Renin Inhibitors
631
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
631
Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
432
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432

